Zomedica Corp [AMEX: ZOM] surged by $0.0 during the normal trading session on Tuesday and reaching a high of $0.20 during the day while it closed the day at $0.19. The company report on November 2, 2023 at 6:30 AM that Zomedica to Report Third Quarter 2023 Financial Results and Provide Business Update on November 13 at 4:30 p.m. ET.
Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or the “Company”), a veterinary health company offering point-of-care diagnostic and therapeutic products for companion animals, will host a conference call and audio-only webcast on Monday, November 13, 2023 at 4:30 p.m. ET to discuss the Company’s operational and financial highlights for its third quarter ended September 30, 2023. A question-and-answer session will follow management’s prepared remarks.
Event: Zomedica Q3 2023 Financial Results Conference CallDate: Monday, November 13, 2023Time: 4:30 p.m. Eastern TimeLive Call: +1-877-407-0789 (U.S. Toll-Free) or +1-201-689-8562 (International)Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1641216&tp_key=4fcf4cae49.
Zomedica Corp stock has also gained 14.88% of its value over the past 7 days. However, ZOM stock has declined by -5.81% in the 3 months of the year. Over the past six months meanwhile, it has lost -8.96% and gained 18.40% year-on date.
The market cap for ZOM stock reached $189.13 million, with 979.95 million shares outstanding and 965.81 million shares in the current float. Compared to the average trading volume of 3.48M shares, ZOM reached a trading volume of 4849566 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Zomedica Corp [ZOM]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ZOM shares is $0.44 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ZOM stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Dawson James have made an estimate for Zomedica Corp shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 06, 2023.
The Average True Range (ATR) for Zomedica Corp is set at 0.01, with the Price to Sales ratio for ZOM stock in the period of the last 12 months amounting to 8.43. The Price to Book ratio for the last quarter was 0.73, with the Price to Cash per share for the same quarter was set at 0.13.
ZOM stock trade performance evaluation
Zomedica Corp [ZOM] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 14.88. With this latest performance, ZOM shares gained by 13.93% in over the last four-week period, additionally sinking by -8.96% over the last 6 months – not to mention a drop of -14.03% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ZOM stock in for the last two-week period is set at 66.76, with the RSI for the last a single of trading hit 73.73, and the three-weeks RSI is set at 61.43 for Zomedica Corp [ZOM]. The present Moving Average for the last 50 days of trading for this stock 0.1718, while it was recorded at 0.1823 for the last single week of trading, and 0.2060 for the last 200 days.
Zomedica Corp [ZOM]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Zomedica Corp [ZOM] shares currently have an operating margin of -115.81 and a Gross Margin at +50.77. Zomedica Corp’s Net Margin is presently recorded at -89.88.
Return on Total Capital for ZOM is now -8.10, given the latest momentum, and Return on Invested Capital for the company is -6.30. Return on Equity for this stock declined to -6.32, with Return on Assets sitting at -6.08. When it comes to the capital structure of this company, Zomedica Corp [ZOM] has a Total Debt to Total Equity ratio set at 0.65. Additionally, ZOM Total Debt to Total Capital is recorded at 0.65, with Total Debt to Total Assets ending up at 0.62. Long-Term Debt to Equity for the company is recorded at 0.41, with the Long-Term Debt to Total Capital now at 0.41.
Reflecting on the efficiency of the workforce at the company, Zomedica Corp [ZOM] managed to generate an average of -$200,176 per employee. Receivables Turnover for the company is 14.40 with a Total Asset Turnover recorded at a value of 0.07.Zomedica Corp’s liquidity data is similarly interesting compelling, with a Quick Ratio of 18.86 and a Current Ratio set at 19.37.
Zomedica Corp [ZOM]: Institutional Ownership
The top three institutional holders of ZOM stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2579%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $201.66 billion in ZOM stocks shares; and BERKSHIRE HATHAWAY INC, currently with $177.59 billion in ZOM stock with ownership which is approximately 5.7994%.
